Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study
Titel:
Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study
Auteur:
Hu, Yu Liu, Xiaofan Zhou, Hu Wang, Shujie Huang, Ruibin Wang, Yi Du, Xin Sun, Jing Zhou, Zeping Yan, Zhenyu Chen, Wenming Wang, Wei Liu, Qingchi Zeng, Qingshu Gong, Yuping Yin, Jie Shen, Xuliang Ye, Baodong Chen, Yun Xu, Yajing Sun, Huiping Cheng, Yunfeng Liu, Zhuogang Wang, Chunling Yuan, Guolin Zhang, Xiaohui Li, Xin Cheng, Peng Guo, Xinhong Jiang, Zhongxing Yang, Feng'e Yang, Linhua Luo, Chengwei Xiao, Taiwu Fu, Sisi Yin, Hongyan Guo, Xiaojun Xu, Qian Fan, Songhua Shi, Michael M Su, Weiguo Mei, Heng Yang, Renchi